Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

VVY

Vivoryon Therapeut (VVY)

Vivoryon Therapeut
Date:
Sort by:
 Showing the most relevant articles for your search:EU:VVY
DateTimeSourceHeadlineSymbolCompany
24/04/202415:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic UpdatesEU:VVYVivoryon Therapeut
16/04/202415:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024EU:VVYVivoryon Therapeut
15/03/202417:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Changes to Board CompositionEU:VVYVivoryon Therapeut
04/03/202417:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
08/01/202417:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024EU:VVYVivoryon Therapeut
06/12/202317:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
28/11/202317:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023EU:VVYVivoryon Therapeut
07/11/202317:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
07/11/202317:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Present at Upcoming Investor ConferenceEU:VVYVivoryon Therapeut
26/10/202316:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose DecisionEU:VVYVivoryon Therapeut
23/10/202316:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
23/10/202316:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated DoseEU:VVYVivoryon Therapeut
18/10/202300:32GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
18/10/202300:32GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion LeadersEU:VVYVivoryon Therapeut
05/10/202316:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
05/10/202316:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Virtual R&D Event with Key Opinion Leaders and Upcoming Conference ParticipationEU:VVYVivoryon Therapeut
15/09/202321:57GlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting Approved Appointment of New Executive Directors to the BoardEU:VVYVivoryon Therapeut
07/09/202315:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports H1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
31/08/202315:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Half Year 2023 Financial Results and Operational Progress on September 07, 2023EU:VVYVivoryon Therapeut
05/08/202307:35GlobeNewswire Inc.Vivoryon Therapeutics N.V. Extraordinary General Meeting to Confirm New Executive Director Appointments to the Board, Being Held on September 15, 2023EU:VVYVivoryon Therapeut
05/08/202307:30GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces Proposed Appointment of Dr. Frank Weber as Chief Executive OfficerEU:VVYVivoryon Therapeut
16/07/202317:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s DiseaseEU:VVYVivoryon Therapeut
22/06/202302:02GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Outcome of 2023 Annual General MeetingEU:VVYVivoryon Therapeut
16/06/202301:49GlobeNewswire Inc.Vivoryon Therapeutics N.V. Announces CEO Transition PlanEU:VVYVivoryon Therapeut
01/06/202315:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Participate in Upcoming ConferencesEU:VVYVivoryon Therapeut
26/05/202315:39GlobeNewswire Inc.Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25 MillionEU:VVYVivoryon Therapeut
26/05/202301:50GlobeNewswire Inc.Vivoryon Therapeutics Launches Capital Increase by Way of an Accelerated Bookbuild OfferingEU:VVYVivoryon Therapeut
16/05/202315:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational ProgressEU:VVYVivoryon Therapeut
09/05/202315:02GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Hold its 2023 Annual General Meeting on June 21, 2023EU:VVYVivoryon Therapeut
09/05/202315:00GlobeNewswire Inc.Vivoryon Therapeutics N.V. to Report Q1 2023 Financial Results and Operational Progress on May 16, 2023EU:VVYVivoryon Therapeut
 Showing the most relevant articles for your search:EU:VVY